TPWA
TGTX icon

Twin Peaks Wealth Advisors’s TG Therapeutics TGTX Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.7K Buy
+323
New +$9.63K ﹤0.01% 1029
2025
Q3 		– Sell
-385
Closed -$10.4K – 1924
2025
Q2 		$10.4K Buy
+385
New +$14.3K ﹤0.01% 914

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Twin Peaks Wealth Advisors's TGTX Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in TG Therapeutics (TGTX) in Q1 2026: 323 shares worth $10.7K. The stake represents ﹤0.01% of the portfolio and ranks #1029 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in TGTX as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in TGTX in Q2 2025 and has held it in 2 quarters since. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Twin Peaks Wealth Advisors held 323 shares of TG Therapeutics worth $10.7K as of Q1 2026.
  • TG Therapeutics was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • TG Therapeutics made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #1029 holding.
  • Twin Peaks Wealth Advisors first reported a position in TG Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.